REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1601773
This article is part of the Research TopicCellular Immunotherapy: Transforming Cancer TreatmentView all 9 articles
Tumor-Infiltrating Lymphocytes in Cancer Immunotherapy: From Chemotactic Recruitment to Translational Modeling
Provisionally accepted- 1University Medical Center Mother Teresa (QSUT), Tirana, Tirana, Albania
- 2Department of Pathophysiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
- 3Faculty of Engineering and Natural Sciences, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina
- 4Institute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece
- 5Bioinformatics and Functional Genomics Group, Cancer Research Center (CiC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Cientificas (CSIC) & University of Salamanca (USAL), Salamanca, Spain
- 6Stefan S. Nicolau Institute of Virology, Bucharest, Romania
- 7Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Tumor-infiltrating lymphocytes (TILs) are a diverse population of immune cells that play a central role in tumor immunity and have emerged as critical mediators in cancer immunotherapy. This review explores the phenotypic and functional diversity of TILs—including CD8⁺ cytotoxic T cells, CD4⁺ helper T cells, regulatory T cells, B cells, and natural killer (NK) cells—and their dynamic interactions within the tumor microenvironment (TME). While TILs can drive tumor regression, their activity is often hindered by immune checkpoint signaling, metabolic exhaustion, and stromal exclusion.We highlight TIL recruitment, activation, and polarization mechanisms, focusing on chemokine gradients, endothelial adhesion molecules, and dendritic cell-mediated priming. Special emphasis is placed on preclinical models that evaluate TIL function, including 3D tumor spheroids, organoid co-cultures, syngeneic mouse models, and humanized systems. These provide valuable platforms for optimizing TIL-based therapies. Furthermore, we examine the prognostic and predictive value of TILs across cancer types, their role in adoptive cell therapy, and the challenges of translating preclinical success into clinical efficacy.Emerging technologies such as single-cell sequencing, neoantigen prediction, and biomaterial platforms are transforming our understanding of TIL biology and enhancing their therapeutic potential. Innovative strategies—ranging from genetic engineering and combination therapies to targeted modulation of the TME—are being developed to overcome resistance mechanisms and improve TIL persistence, infiltration, and cytotoxicity.This review integrates current advances in TIL research and therapy, offering a comprehensive foundation for future clinical translation. TILs hold significant promise as both biomarkers and therapeutic agents, and with continued innovation, they are poised to become a cornerstone of personalized cancer immunotherapy.
Keywords: Tumor-infiltrating lymphocytes, Tumor Microenvironment, Immunotherapy, adoptive cell transfer, Experimental models
Received: 28 Mar 2025; Accepted: 01 May 2025.
Copyright: © 2025 Kraja, Jurisic, Hromić-Jahjefendić, Rossopoulou, Katsila, Mirjacic Martinovic, De Las Rivas, Diaconu and Szoor. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Arpad Szoor, Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, 4032, Hungary
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.